Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.
The SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.
Sixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.
The primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GCA group | Patients with new-onset GCA who completed the SONIC-GCA (main study) baseline visit and who received 48 hours or less of glucocorticoids and less or equal to 160mg of oral prednisone equivalent. Study visits : Baseline, then days 3, 7, 10, 14, 21, 28, and Month 2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Optic Nerve Sheath Ultrasound | Diagnostic Test | Optic nerve sheath ultrasound will be performed in combination with a digital retinal fundoscopy. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in mean ONSD (in mm) from day 0 to day 28 | To quantify the change in mean ONSD (in mm, by ultrasound) between baseline (Day 0) and Day 28 after GC initiation in patients with GCA exposed to ≤ 48 hours and ≤ 120 mg prednisone-equivalent before baseline. | Day 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in mean ONSD (in mm, using ultrasound) from day 0 to day 14 | To quantify the change in mean ONSD between baseline (Day 0) and Day14 after GC initiation in patients with GCA exposed to ≤ 48 hours and ≤ 120 mg prednisone-equivalent before baseline. | Day 14 |
| Change in mean ONSD (in mm, using ultrasound) from day 0 to month 2 |
Not provided
Inclusion Criteria:
Participants must be enrolled in SONIC-GCA and must have:
Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline.
Ability and willingness to provide written informed consent.
Agreement to complete the SONIC-TIME intensive follow-up schedule.
Exclusion Criteria:
1) Concurrent participation in a blinded interventional pharmaceutical clinical trial.
Not provided
Not provided
Not provided
Not provided
Eligible patients will consist of those who consult at our GCA fast-track clinic, have completed the SONIC-GCA baseline procedures, and have received a diagnosis of GCA on that visit.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Paul Makhzoum, MD, MSc | Contact | 514-338-2222 | jean-paul.makhzoum@umontreal.ca |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Paul Makhzoum, MD, MSc | CISSS du Nord-de-l'ile de Montreal | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal | Montreal | Quebec | H4J1C5 | Canada |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Temporal artery ultrasound | Diagnostic Test | With measurement of the intima-media complex and calculation of the OGUS. |
|
| Bloodwork : CRP and ESR | Diagnostic Test | At each visit |
|
To model ONSD change over the first eight weeks using with time-updated cumulative GC exposure. |
| Month 2 |
| Association between cumulative glucocorticoids (GCs, in mg) and ONSD (in mm, by ultrasound) | To determine the dose-response relationship between ONSD and cumulative GC exposure. | Month 2 |
| Association between IV methylprednisolone (binary : yes or no) and ONSD (in mm, by ultrasound) | To evaluate the influence of IV methylprednisolone on ONSD evolution. | Month 2 |
| Association between immunosuppressive therapy (categorical, documented using medication list) and ONSD (in mm, by ultrasound) | To assess the impact of early initiated steroid-sparing therapies initiated as standard of care on ONSD trajectory. | Month 2 |
| ONSD threshold (from the SONIC-GCA trial) performance over time | To evaluate the time-adjusted ONSD performance based on the established SONIC-GCA ONSD cutoff. | Month 2 |
| Time (in days) to ONSD normalization | To estimate the adjusted time to first attainment of an ONSD value below the established SONIC-GCA ONSD cutoff. | Month 2 |
| Association between inflammatory markers and ONSD | To quantify correlations between ONSD and systemic inflammatory biomarkers over the early therapy period. | Month 2 |
| Association between OGUS and ONSD | To examine associations between ONSD and the temporal artery ultrasound OGUS score over the early therapy period. | Month 2 |
| Association between digital retinal fundoscopy and ONSD (in mm, by ultrasound) | To compare ONSD trajectories between participants with and without GCA-related retinal abnormalities on digital retinal fundoscopy. | Month 2 |
| ID | Term |
|---|---|
| D013700 | Giant Cell Arteritis |
| D009901 | Optic Nerve Diseases |
| D004194 | Disease |
| ID | Term |
|---|---|
| D020293 | Vasculitis, Central Nervous System |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001167 | Arteritis |
| D014657 | Vasculitis |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D003389 | Cranial Nerve Diseases |
| D005128 | Eye Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001799 | Blood Sedimentation |
| ID | Term |
|---|---|
| D006403 | Hematologic Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
Not provided
Not provided